Csl Behring
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$76Mgeneral payments (2019-2025)
$997Kresearch payments (2019-2025)
31,615clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Hizentra $2.6M associated (2023-2025)
- Kcentra $2.0M associated (2023-2025)
- Hemgenix $1.9M associated (2023-2025)
- Andembry $1.5M associated (2023-2025)
- Haegarda $688K associated (2023-2025)
- Idelvion $282K associated (2023-2025)
- Privigen $239K associated (2023-2025)
- Zemaira $108K associated (2023-2025)
- Riastap $101K associated (2023-2025)
- Berinert $66K associated (2023-2025)
- Afstyla $14K associated (2023-2025)
- Humate-P $6,029 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Amy Schmidt | Denver, CO | Hematology & Oncology | $2,772,561.25 |
| Majed Refaai | Rochester, NY | Clinical Pathology | $2,057,233.88 |
| Michael Gibson | Smyrna, GA | Internal Medicine | $1,153,447.68 |
| Kwabena Oteng | Springdale, OH | Family Medicine | $1,087,458.15 |
| Richard Tanner | Indianapolis, IN | Family Medicine | $1,020,585.00 |
| Kenneth Primm | Crawfordsville, IN | Anesthesiology | $1,008,595.20 |
| Christopher Jennings | Anderson, SC | Obstetrics & Gynecology | $942,237.56 |
| Stephen Martin | Marietta, GA | Emergency Medicine | $915,132.40 |
| John Mckinney | Tyler, TX | Emergency Medicine | $906,181.22 |
| Andrzej Kalinski | Rock Hill, SC | $857,079.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.